Infectious Disease In-vitro Diagnostics Market by Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

Description

Persistence Market Research presents an extensive analysis of the global Infectious Disease In-vitro Diagnostics (IVD) Market, providing insights into market dynamics, growth drivers, challenges, and emerging trends. This report serves as a comprehensive guide for stakeholders, offering detailed data and statistics for navigating the market landscape.

The global infectious disease in-vitro diagnostics market is poised for significant growth between 2024 and 2031, driven by the increasing prevalence of infectious diseases worldwide. With a projected CAGR of 4.4% during this period, the market is estimated to expand from USD 66.8 billion in 2024 to USD 90.2 billion by 2031.

Key Insights:

Estimated Market Value (2024): USD 66.8 Billion
Projected Market Value (2031): USD 90.2 Billion
Global Market Growth Rate (CAGR 2024 to 2031): 4.4%

Infectious Disease In-vitro Diagnostics Market - Report Scope:

In-vitro diagnostics play a crucial role in the detection and management of infectious diseases, providing rapid and accurate results for effective patient care. The market encompasses a wide range of diagnostic tests, including molecular assays, immunoassays, and point-of-care tests, designed to detect various infectious agents such as bacteria, viruses, and parasites.

The increasing incidence of infectious diseases, fueled by factors such as globalization, urbanization, and antimicrobial resistance, drives the demand for diagnostic testing. Furthermore, the ongoing COVID-19 pandemic has underscored the importance of robust diagnostic infrastructure and testing capabilities to control disease spread and manage public health crises.

Market Growth Drivers:

Several factors contribute to the growth of the infectious disease IVD market, including the rising incidence of infectious diseases such as HIV/AIDS, tuberculosis, malaria, and hepatitis. Additionally, the emergence of new infectious agents and the re-emergence of existing pathogens pose significant public health challenges, necessitating enhanced diagnostic capabilities.

Advancements in diagnostic technologies, including molecular diagnostics, next-generation sequencing, and rapid point-of-care testing, enable faster and more accurate detection of infectious agents. Moreover, increased healthcare spending, government initiatives to combat infectious diseases, and growing awareness about the importance of early diagnosis further drive market growth.

Market Restraints:

Despite its positive growth outlook, the infectious disease IVD market faces certain challenges, including regulatory hurdles, reimbursement issues, and supply chain disruptions. Stringent regulatory requirements for diagnostic test approval and reimbursement limitations can hinder market access for manufacturers, particularly small and medium-sized enterprises.

Furthermore, the complexity and cost of implementing diagnostic testing infrastructure, especially in resource-limited settings, pose challenges to market expansion. Additionally, the variability in test performance and the potential for false-positive or false-negative results can impact diagnostic accuracy and patient outcomes, leading to concerns among healthcare providers and patients.

Market Opportunities:

The infectious disease IVD market presents numerous opportunities for innovation and expansion, particularly in the development of novel diagnostic technologies and test platforms. Advances in molecular diagnostics, including nucleic acid amplification tests and multiplex assays, offer improved sensitivity, specificity, and turnaround time for infectious disease detection.

Furthermore, the integration of artificial intelligence and machine learning algorithms into diagnostic platforms enhances data analysis and interpretation, leading to more accurate and actionable diagnostic insights. Moreover, the increasing adoption of point-of-care testing and decentralized diagnostic solutions enables timely diagnosis and treatment, particularly in underserved and remote areas.

Key Questions Addressed in the Report:

What is the Expected Value CAGR of the Infectious Disease IVD Market from 2024 to 2031?
What are the Key Factors Driving the Growth of the Infectious Disease IVD Market?
Which Region Holds the Largest Market Share in the Infectious Disease IVD Market?
Who are the Key Players in the Global Infectious Disease IVD Market?
What Strategies are Adopted by Leading Companies to Sustain Growth in the Infectious Disease IVD Market?

Competitive Landscape and Business Strategies:

Leading companies in the infectious disease IVD market include Roche Diagnostics, Abbott Laboratories, and bioMerieux SA. These companies focus on product innovation, research and development, and strategic partnerships to maintain their competitive edge.

Strategies such as expanding product portfolios, geographic expansion, and mergers and acquisitions are employed to enhance market presence and gain a competitive advantage. Furthermore, collaborations with healthcare organizations, government agencies, and research institutions facilitate the development and commercialization of novel diagnostic solutions.

Key Companies Profiled:

Roche Diagnostics
Abbott Laboratories
bioMerieux SA
Siemens Healthineers AG
Becton, Dickinson and Company
Thermo Fisher Scientific, Inc.
Danaher Corporation
Hologic, Inc.
QIAGEN N.V.
Cepheid Inc.

Infectious Disease IVD Market Segmentation:

By Product Type:

Instruments
Reagents
Services

By Technology:

Immunoassay
Molecular Diagnostics
Microbiology
Other Technologies

By Application:

MRSA
Streptococcus
Clostridium Difficile
Respiratory Virus
TB and Drug-resistant TB
Gonorrhea
HPV
HIV
Hepatitis C
Hepatitis B
COVID-19
Other Applications

By End-use:

Point of care
Central Laboratories
Other End-uses

By Region:

North America
Latin America
Europe
Asia Pacific
Middle East & Africa

Product Code: PMRREP33205

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics
- 3.1.1. Drivers
- 3.1.2. Restraints
- 3.1.3. Opportunity
- 3.1.4. Trends
3.2. Scenario Forecast
- 3.2.1. Demand in Optimistic Scenario
- 3.2.2. Demand in Likely Scenario
- 3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Investment Feasibility Matrix
3.6. PESTLE and Porter's Analysis
3.7. Regulatory Landscape
- 3.7.1. By Key Regions
- 3.7.2. By Key Countries
3.8. Regional Parent Market Outlook

4. Global Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast, 2024-2031

4.1. Historical Market Size Value (US$ Mn) Analysis, 2019-2023
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2024-2031
- 4.2.1. Y-o-Y Growth Trend Analysis
- 4.2.2. Absolute $ Opportunity Analysis

5. Global Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Product Type

5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Product Type, 2019-2023
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Product Type, 2024-2031
- 5.3.1. Instruments
- 5.3.2. Reagents
- 5.3.3. Services
5.4. Y-o-Y Growth Trend Analysis By Product Type, 2019-2023
5.5. Absolute $ Opportunity Analysis By Product Type, 2024-2031

6. Global Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Technology

6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Technology, 2019-2023
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Technology, 2024-2031
- 6.3.1. Immunoassay
- 6.3.2. Molecular Diagnostics
- 6.3.3. Microbiology
- 6.3.4. Other Technologies
6.4. Y-o-Y Growth Trend Analysis By Technology, 2019-2023
6.5. Absolute $ Opportunity Analysis By Technology, 2024-2031

7. Global Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Application

7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By Application, 2019-2023
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Application, 2024-2031
- 7.3.1. MRSA
- 7.3.2. Streptococcus
- 7.3.3. Clostridium Difficile
- 7.3.4. Respiratory Virus
- 7.3.5. TB and Drug-resistant TB
- 7.3.6. Gonorrhea
- 7.3.7. HPV
- 7.3.8. HIV
- 7.3.9. Hepatitis C
- 7.3.10. Hepatitis B
- 7.3.11. COVID-19
- 7.3.12. Other Applications
7.4. Y-o-Y Growth Trend Analysis By Application, 2019-2023
7.5. Absolute $ Opportunity Analysis By Application, 2024-2031

8. Global Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By End-use

8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Mn) Analysis By End-use, 2019-2023
8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End-use, 2024-2031
- 8.3.1. Point of care
- 8.3.2. Central Laboratories
- 8.3.3. Other End-uses
8.4. Y-o-Y Growth Trend Analysis By End-use, 2019-2023
8.5. Absolute $ Opportunity Analysis By End-use, 2024-2031

9. Global Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Region

9.1. Introduction
9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2019-2023
9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2024-2031
- 9.3.1. North America
- 9.3.2. Latin America
- 9.3.3. Europe
- 9.3.4. Asia Pacific
- 9.3.5. Middle East and Africa
9.4. Market Attractiveness Analysis By Region

10. North America Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Country

10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 10.2.1. By Country
  - 10.2.1.1. U.S.
  - 10.2.1.2. Canada
- 10.2.2. By Product Type
- 10.2.3. By Technology
- 10.2.4. By Application
- 10.2.5. By End-use
10.3. Market Attractiveness Analysis
- 10.3.1. By Country
- 10.3.2. By Product Type
- 10.3.3. By Technology
- 10.3.4. By Application
- 10.3.5. By End-use
10.4. Key Takeaways

11. Latin America Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Country

11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 11.2.1. By Country
  - 11.2.1.1. Brazil
  - 11.2.1.2. Mexico
  - 11.2.1.3. Rest of Latin America
- 11.2.2. By Product Type
- 11.2.3. By Technology
- 11.2.4. By Application
- 11.2.5. By End-use
11.3. Market Attractiveness Analysis
- 11.3.1. By Country
- 11.3.2. By Product Type
- 11.3.3. By Technology
- 11.3.4. By Application
- 11.3.5. By End-use
11.4. Key Takeaways

12. Europe Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Country

12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 12.2.1. By Country
  - 12.2.1.1. Germany
  - 12.2.1.2. U.K.
  - 12.2.1.3. France
  - 12.2.1.4. Spain
  - 12.2.1.5. Italy
  - 12.2.1.6. Russia
  - 12.2.1.7. Rest of Europe
- 12.2.2. By Product Type
- 12.2.3. By Technology
- 12.2.4. By Application
- 12.2.5. By End-use
12.3. Market Attractiveness Analysis
- 12.3.1. By Country
- 12.3.2. By Product Type
- 12.3.3. By Technology
- 12.3.4. By Application
- 12.3.5. By End-use
12.4. Key Takeaways

13. Asia Pacific Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Country

13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 13.2.1. By Country
  - 13.2.1.1. China
  - 13.2.1.2. Japan
  - 13.2.1.3. India
  - 13.2.1.4. South Korea
  - 13.2.1.5. Australia
  - 13.2.1.6. Rest of APAC
- 13.2.2. By Product Type
- 13.2.3. By Technology
- 13.2.4. By Application
- 13.2.5. By End-use
13.3. Market Attractiveness Analysis
- 13.3.1. By Country
- 13.3.2. By Product Type
- 13.3.3. By Technology
- 13.3.4. By Application
- 13.3.5. By End-use
13.4. Key Takeaways

14. Middle East and Africa Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Country

14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 14.2.1. By Country
  - 14.2.1.1. South Africa
  - 14.2.1.2. Saudi Arabia
  - 14.2.1.3. UAE
  - 14.2.1.4. Israel
  - 14.2.1.5. Rest of MEA
- 14.2.2. By Product Type
- 14.2.3. By Technology
- 14.2.4. By Application
- 14.2.5. By End-use
14.3. Market Attractiveness Analysis
- 14.3.1. By Country
- 14.3.2. By Product Type
- 14.3.3. By Technology
- 14.3.4. By Application
- 14.3.5. By End-use
14.4. Key Takeaways

15. Key Countries Infectious Disease In-vitro Diagnostics Market Analysis

15.1. U.S.
- 15.1.1. Pricing Analysis
- 15.1.2. Market Share Analysis, 2024
  - 15.1.2.1. By Product Type
  - 15.1.2.2. By Technology
  - 15.1.2.3. By Application
  - 15.1.2.4. By End-use
15.2. Canada
- 15.2.1. Pricing Analysis
- 15.2.2. Market Share Analysis, 2024
  - 15.2.2.1. By Product Type
  - 15.2.2.2. By Technology
  - 15.2.2.3. By Application
  - 15.2.2.4. By End-use
15.3. Brazil
- 15.3.1. Pricing Analysis
- 15.3.2. Market Share Analysis, 2024
  - 15.3.2.1. By Product Type
  - 15.3.2.2. By Technology
  - 15.3.2.3. By Application
  - 15.3.2.4. By End-use
15.4. Mexico
- 15.4.1. Pricing Analysis
- 15.4.2. Market Share Analysis, 2024
  - 15.4.2.1. By Product Type
  - 15.4.2.2. By Technology
  - 15.4.2.3. By Application
  - 15.4.2.4. By End-use
15.5. Germany
- 15.5.1. Pricing Analysis
- 15.5.2. Market Share Analysis, 2024
  - 15.5.2.1. By Product Type
  - 15.5.2.2. By Technology
  - 15.5.2.3. By Application
  - 15.5.2.4. By End-use
15.6. U.K.
- 15.6.1. Pricing Analysis
- 15.6.2. Market Share Analysis, 2024
  - 15.6.2.1. By Product Type
  - 15.6.2.2. By Technology
  - 15.6.2.3. By Application
  - 15.6.2.4. By End-use
15.7. France
- 15.7.1. Pricing Analysis
- 15.7.2. Market Share Analysis, 2024
  - 15.7.2.1. By Product Type
  - 15.7.2.2. By Technology
  - 15.7.2.3. By Application
  - 15.7.2.4. By End-use
15.8. Spain
- 15.8.1. Pricing Analysis
- 15.8.2. Market Share Analysis, 2024
  - 15.8.2.1. By Product Type
  - 15.8.2.2. By Technology
  - 15.8.2.3. By Application
  - 15.8.2.4. By End-use
15.9. Italy
- 15.9.1. Pricing Analysis
- 15.9.2. Market Share Analysis, 2024
  - 15.9.2.1. By Product Type
  - 15.9.2.2. By Technology
  - 15.9.2.3. By Application
  - 15.9.2.4. By End-use
15.10. Russia
- 15.10.1. Pricing Analysis
- 15.10.2. Market Share Analysis, 2024
  - 15.10.2.1. By Product Type
  - 15.10.2.2. By Technology
  - 15.10.2.3. By Application
  - 15.10.2.4. By End-use
15.11. China
- 15.11.1. Pricing Analysis
- 15.11.2. Market Share Analysis, 2024
  - 15.11.2.1. By Product Type
  - 15.11.2.2. By Technology
  - 15.11.2.3. By Application
  - 15.11.2.4. By End-use
15.12. Japan
- 15.12.1. Pricing Analysis
- 15.12.2. Market Share Analysis, 2024
  - 15.12.2.1. By Product Type
  - 15.12.2.2. By Technology
  - 15.12.2.3. By Application
  - 15.12.2.4. By End-use
15.13. India
- 15.13.1. Pricing Analysis
- 15.13.2. Market Share Analysis, 2024
  - 15.13.2.1. By Product Type
  - 15.13.2.2. By Technology
  - 15.13.2.3. By Application
  - 15.13.2.4. By End-use
15.14. South Korea
- 15.14.1. Pricing Analysis
- 15.14.2. Market Share Analysis, 2024
  - 15.14.2.1. By Product Type
  - 15.14.2.2. By Technology
  - 15.14.2.3. By Application
  - 15.14.2.4. By End-use
15.15. Australia
- 15.15.1. Pricing Analysis
- 15.15.2. Market Share Analysis, 2024
  - 15.15.2.1. By Product Type
  - 15.15.2.2. By Technology
  - 15.15.2.3. By Application
  - 15.15.2.4. By End-use
15.16. South Africa
- 15.16.1. Pricing Analysis
- 15.16.2. Market Share Analysis, 2024
  - 15.16.2.1. By Product Type
  - 15.16.2.2. By Technology
  - 15.16.2.3. By Application
  - 15.16.2.4. By End-use
15.17. Saudi Arabia
- 15.17.1. Pricing Analysis
- 15.17.2. Market Share Analysis, 2024
  - 15.17.2.1. By Product Type
  - 15.17.2.2. By Technology
  - 15.17.2.3. By Application
  - 15.17.2.4. By End-use
15.18. UAE
- 15.18.1. Pricing Analysis
- 15.18.2. Market Share Analysis, 2024
  - 15.18.2.1. By Product Type
  - 15.18.2.2. By Technology
  - 15.18.2.3. By Application
  - 15.18.2.4. By End-use
15.19. Israel
- 15.19.1. Pricing Analysis
- 15.19.2. Market Share Analysis, 2024
  - 15.19.2.1. By Product Type
  - 15.19.2.2. By Technology
  - 15.19.2.3. By Application
  - 15.19.2.4. By End-use

16. Market Structure Analysis

16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
- 16.3.1. By Regional
- 16.3.2. By Product Type
- 16.3.3. By Technology
- 16.3.4. By Application
- 16.3.5. By End-use

17. Competition Analysis

17.1. Competition Deep Dive
- 17.1.1. Becton, Dickinson and Company
  - 17.1.1.1. Overview
  - 17.1.1.2. Product Portfolio
  - 17.1.1.3. Profitability by Market Segments
  - 17.1.1.4. Sales Footprint
  - 17.1.1.5. Strategy Overview
    - 17.1.1.5.1. Marketing Strategy
- 17.1.2. bioMerieux SA
  - 17.1.2.1. Overview
  - 17.1.2.2. Product Portfolio
  - 17.1.2.3. Profitability by Market Segments
  - 17.1.2.4. Sales Footprint
  - 17.1.2.5. Strategy Overview
    - 17.1.2.5.1. Marketing Strategy
- 17.1.3. Abbott
  - 17.1.3.1. Overview
  - 17.1.3.2. Product Portfolio
  - 17.1.3.3. Profitability by Market Segments
  - 17.1.3.4. Sales Footprint
  - 17.1.3.5. Strategy Overview
    - 17.1.3.5.1. Marketing Strategy
- 17.1.4. Quidel Corporation
  - 17.1.4.1. Overview
  - 17.1.4.2. Product Portfolio
  - 17.1.4.3. Profitability by Market Segments
  - 17.1.4.4. Sales Footprint
  - 17.1.4.5. Strategy Overview
    - 17.1.4.5.1. Marketing Strategy
- 17.1.5. OraSure Technologies, Inc
  - 17.1.5.1. Overview
  - 17.1.5.2. Product Portfolio
  - 17.1.5.3. Profitability by Market Segments
  - 17.1.5.4. Sales Footprint
  - 17.1.5.5. Strategy Overview
    - 17.1.5.5.1. Marketing Strategy
- 17.1.6. Hologic Inc.
  - 17.1.6.1. Overview
  - 17.1.6.2. Product Portfolio
  - 17.1.6.3. Profitability by Market Segments
  - 17.1.6.4. Sales Footprint
  - 17.1.6.5. Strategy Overview
    - 17.1.6.5.1. Marketing Strategy
- 17.1.7. Cepheid
  - 17.1.7.1. Overview
  - 17.1.7.2. Product Portfolio
  - 17.1.7.3. Profitability by Market Segments
  - 17.1.7.4. Sales Footprint
  - 17.1.7.5. Strategy Overview
    - 17.1.7.5.1. Marketing Strategy
- 17.1.8. Qiagen
  - 17.1.8.1. Overview
  - 17.1.8.2. Product Portfolio
  - 17.1.8.3. Profitability by Market Segments
  - 17.1.8.4. Sales Footprint
  - 17.1.8.5. Strategy Overview
    - 17.1.8.5.1. Marketing Strategy
- 17.1.9. F. Hoffmann-La Roche Ltd.
  - 17.1.9.1. Overview
  - 17.1.9.2. Product Portfolio
  - 17.1.9.3. Profitability by Market Segments
  - 17.1.9.4. Sales Footprint
  - 17.1.9.5. Strategy Overview
    - 17.1.9.5.1. Marketing Strategy
- 17.1.10. Siemens Healthcare GmbH
  - 17.1.10.1. Overview
  - 17.1.10.2. Product Portfolio
  - 17.1.10.3. Profitability by Market Segments
  - 17.1.10.4. Sales Footprint
  - 17.1.10.5. Strategy Overview
    - 17.1.10.5.1. Marketing Strategy
- 17.1.11. Bio-Rad Laboratories, Inc.
  - 17.1.11.1. Overview
  - 17.1.11.2. Product Portfolio
  - 17.1.11.3. Profitability by Market Segments
  - 17.1.11.4. Sales Footprint
  - 17.1.11.5. Strategy Overview
    - 17.1.11.5.1. Marketing Strategy